Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Immunoglobulins in the Treatment of Pneumonia: Evidence Synopsis

Immunoglobulins (IG), particularly intravenous immunoglobulin (IVIG), have been studied as adjunctive therapy in certain cases of pneumonia, especially in immunocompromised patients or those with severe infections. The scientific rationale is based on their ability to provide passive immunity by supplying exogenous antibodies that can help neutralize pathogens and modulate immune responses.

Clinical studies and meta-analyses have primarily investigated IVIG in severe community-acquired pneumonia, ventilator-associated pneumonia, or pneumonia in neonates and immunodeficient individuals. Results are mixed: some small randomized controlled trials and observational studies suggest a reduction in mortality or improvement in clinical outcomes, particularly in patients with low endogenous immunoglobulin levels or overwhelming sepsis. However, larger and more rigorous trials often fail to demonstrate a significant benefit in unselected patient populations.

Current guidelines, including those from the Infectious Diseases Society of America (IDSA) and other expert bodies, do not recommend routine use of immunoglobulins for bacterial or viral pneumonia in immunocompetent individuals due to insufficient evidence. Their use is generally reserved for select cases, such as patients with proven immunoglobulin deficiencies, certain viral pneumonias in immunocompromised hosts, or refractory septic shock.

In summary, while there is scientific investigation and some support for specific populations, the overall strength of evidence is moderate and does not justify routine use for most patients with pneumonia.

More about Immunoglobulins
More about Pneumonia

Other ingredients used for Pneumonia

Other health conditions supported by Immunoglobulins

Products containing Immunoglobulins